UY25544A1 - Forma de dosificación de nefazodona - Google Patents
Forma de dosificación de nefazodonaInfo
- Publication number
- UY25544A1 UY25544A1 UY25544A UY25544A UY25544A1 UY 25544 A1 UY25544 A1 UY 25544A1 UY 25544 A UY25544 A UY 25544A UY 25544 A UY25544 A UY 25544A UY 25544 A1 UY25544 A1 UY 25544A1
- Authority
- UY
- Uruguay
- Prior art keywords
- nefazodone
- release
- compositions
- dosage form
- demonstrating
- Prior art date
Links
- 229960001800 nefazodone Drugs 0.000 title abstract 4
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 title abstract 4
- 239000002552 dosage form Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000013265 extended release Methods 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 229960002441 nefazodone hydrochloride Drugs 0.000 abstract 1
- DYCKFEBIOUQECE-UHFFFAOYSA-N nefazodone hydrochloride Chemical compound [H+].[Cl-].O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 DYCKFEBIOUQECE-UHFFFAOYSA-N 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Las composiciones de nefazodona de liberación prolongada, que contienen clorhidrato de nefazodona, polímeros de gelificación iónico y no iónico, un agente hidrofílico insoluble, y excipientes opcionales farmacéuticamente aceptables, demuestran liberación de la nefazodona, modulada por el pH. Estas composiciones son formuladas en formas de dosis unitaria para la administración oral mejorada. Los mejoramientos comprenden un perfil prolongado de liberación edl fármaco, proporcionando niveles comparativos de nefazodona con respecto a las formas de dosificación de liberación inmediata y además, que demuestran la falta de un efecto por alimento.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8821198P | 1998-06-05 | 1998-06-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY25544A1 true UY25544A1 (es) | 2001-08-27 |
Family
ID=22210038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY25544A UY25544A1 (es) | 1998-06-05 | 1999-06-04 | Forma de dosificación de nefazodona |
Country Status (20)
Country | Link |
---|---|
US (1) | US6143325A (es) |
EP (1) | EP0966966A3 (es) |
JP (1) | JP2000007567A (es) |
KR (1) | KR20000005930A (es) |
CN (1) | CN1238181A (es) |
AR (1) | AR018862A1 (es) |
AU (1) | AU3319999A (es) |
BR (1) | BR9901782A (es) |
CA (1) | CA2273546A1 (es) |
CO (1) | CO5060477A1 (es) |
HU (1) | HUP9901830A2 (es) |
ID (1) | ID23458A (es) |
IL (1) | IL130022A0 (es) |
NO (1) | NO992692L (es) |
NZ (1) | NZ336001A (es) |
PE (1) | PE20000544A1 (es) |
PL (1) | PL333524A1 (es) |
SG (1) | SG77244A1 (es) |
UY (1) | UY25544A1 (es) |
ZA (1) | ZA993345B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143325A (en) * | 1998-06-05 | 2000-11-07 | Bristol-Myers Squibb Company | Nefazodone dosage form |
EP1428535A1 (en) * | 1998-11-02 | 2004-06-16 | ALZA Corporation | Controlled delivery of antidepressants |
US6706282B1 (en) | 1998-11-02 | 2004-03-16 | Evangeline Cruz | Controlled delivery of phenoxyethyl-substituted 1,2,4-triazolones |
KR20070040421A (ko) * | 1998-11-02 | 2007-04-16 | 알자 코포레이션 | 항우울제의 제어된 전달 |
AU2002306616A1 (en) * | 2001-03-02 | 2002-09-19 | Sepracor Inc. | Composition containing a nefazonoid such as nefazodone and a serotonin-inhibitor such as fluoxetine |
US8329216B2 (en) | 2001-07-06 | 2012-12-11 | Endo Pharmaceuticals Inc. | Oxymorphone controlled release formulations |
WO2003004033A1 (en) | 2001-07-06 | 2003-01-16 | Penwest Pharmaceuticals Company | Sustained release formulations of oxymorphone |
DE60219478T2 (de) | 2001-07-06 | 2008-01-03 | Endo Pharmaceuticals Inc. | Orale gabe von 6-hydroxy-oxymorphon als analgetikum |
US20040220240A1 (en) * | 2001-11-28 | 2004-11-04 | Pellegrini Cara A. | Method of increasing the extent of absorption of tizanidine |
US6455557B1 (en) | 2001-11-28 | 2002-09-24 | Elan Pharmaceuticals, Inc. | Method of reducing somnolence in patients treated with tizanidine |
US7714006B1 (en) | 2001-12-03 | 2010-05-11 | King Pharmaceuticals Research & Development, Inc. | Methods of modifying the bioavailability of metaxalone |
US6407128B1 (en) | 2001-12-03 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Method for increasing the bioavailability of metaxalone |
WO2003099265A2 (de) * | 2002-05-24 | 2003-12-04 | Coester Carl-Fr | Pharmazeutische wirkstoffkombination sowie deren verwendung |
US8487002B2 (en) | 2002-10-25 | 2013-07-16 | Paladin Labs Inc. | Controlled-release compositions |
TWI319713B (en) | 2002-10-25 | 2010-01-21 | Sustained-release tramadol formulations with 24-hour efficacy | |
GB0306604D0 (en) * | 2003-03-21 | 2003-04-30 | Curidium Ltd | Second medical use |
AU2003264002B2 (en) | 2003-08-08 | 2010-09-02 | Valeant International Bermuda | Modified-release tablet of bupropion hydrochloride |
US7893261B2 (en) | 2004-03-26 | 2011-02-22 | Baylor University | Serotonin reuptake inhibitors |
RU2008113439A (ru) | 2005-09-09 | 2009-10-20 | Лабофарм Инк. (CA) | Композиции с замедленным высвобождением лекарственного средства |
US20080287508A1 (en) * | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
US20100160363A1 (en) * | 2008-12-19 | 2010-06-24 | Aaipharma Services Corp. | Extended-release pharmaceutical formulations |
US20100159001A1 (en) * | 2008-12-19 | 2010-06-24 | Cardinal John R | Extended-Release Pharmaceutical Formulations |
WO2012072665A1 (en) | 2010-11-30 | 2012-06-07 | Pharmaneuroboost N.V. | Compositions comprising pipamperone and serotonin antagonist reuptake inhibitors |
JP2011140510A (ja) * | 2011-03-17 | 2011-07-21 | Biovail Lab Inc | 塩酸ブプロピオンの放出調節錠剤 |
CN113842362A (zh) | 2012-11-14 | 2021-12-28 | 格雷斯公司 | 含有生物活性材料与无序无机氧化物的组合物 |
JP6184903B2 (ja) * | 2014-06-04 | 2017-08-23 | ヴァレアント インターナショナル バミューダValeant International Bermuda | 塩酸ブプロピオン放出調節錠剤 |
JP6078514B2 (ja) * | 2014-10-30 | 2017-02-08 | コリア ユナイテッド ファーム,インク | 溶出率向上と副作用発現が最小化されたシルロスタゾール徐放錠 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4792452A (en) * | 1987-07-28 | 1988-12-20 | E. R. Squibb & Sons, Inc. | Controlled release formulation |
US4983398A (en) * | 1987-12-21 | 1991-01-08 | Forest Laboratories, Inc. | Sustained release drug dosage forms containing hydroxypropylmethylcellulose and alkali metal carboxylates |
US5431922A (en) * | 1991-03-05 | 1995-07-11 | Bristol-Myers Squibb Company | Method for administration of buspirone |
US5169638A (en) * | 1991-10-23 | 1992-12-08 | E. R. Squibb & Sons, Inc. | Buoyant controlled release powder formulation |
US5536507A (en) * | 1994-06-24 | 1996-07-16 | Bristol-Myers Squibb Company | Colonic drug delivery system |
EP0859597B1 (en) * | 1995-09-29 | 2003-04-09 | LAM Pharmaceutical Corporation | Sustained release delivery system and long acting narcotic analgesics and antagonists |
WO1997047285A1 (en) * | 1996-06-10 | 1997-12-18 | Depomed, Inc. | Gastric-retentive oral controlled drug delivery system with enhanced retention properties |
US6143325A (en) * | 1998-06-05 | 2000-11-07 | Bristol-Myers Squibb Company | Nefazodone dosage form |
-
1999
- 1999-04-26 US US09/299,959 patent/US6143325A/en not_active Expired - Lifetime
- 1999-05-14 ZA ZA9903345A patent/ZA993345B/xx unknown
- 1999-05-19 IL IL13002299A patent/IL130022A0/xx unknown
- 1999-05-28 NZ NZ336001A patent/NZ336001A/xx unknown
- 1999-06-01 SG SG1999002831A patent/SG77244A1/en unknown
- 1999-06-02 PL PL99333524A patent/PL333524A1/xx not_active Application Discontinuation
- 1999-06-03 AR ARP990102618A patent/AR018862A1/es unknown
- 1999-06-03 NO NO992692A patent/NO992692L/no not_active Application Discontinuation
- 1999-06-03 CA CA002273546A patent/CA2273546A1/en not_active Abandoned
- 1999-06-03 HU HU9901830A patent/HUP9901830A2/hu unknown
- 1999-06-04 UY UY25544A patent/UY25544A1/es not_active Application Discontinuation
- 1999-06-04 JP JP11157499A patent/JP2000007567A/ja active Pending
- 1999-06-04 ID IDP990521D patent/ID23458A/id unknown
- 1999-06-04 KR KR1019990020676A patent/KR20000005930A/ko not_active Application Discontinuation
- 1999-06-04 CO CO99035356A patent/CO5060477A1/es unknown
- 1999-06-04 BR BR9901782-2A patent/BR9901782A/pt not_active IP Right Cessation
- 1999-06-04 EP EP99110777A patent/EP0966966A3/en not_active Withdrawn
- 1999-06-04 AU AU33199/99A patent/AU3319999A/en not_active Abandoned
- 1999-06-04 PE PE1999000481A patent/PE20000544A1/es not_active Application Discontinuation
- 1999-06-07 CN CN99108308A patent/CN1238181A/zh active Pending
Also Published As
Publication number | Publication date |
---|---|
EP0966966A2 (en) | 1999-12-29 |
CO5060477A1 (es) | 2001-07-30 |
CA2273546A1 (en) | 1999-10-10 |
BR9901782A (pt) | 2000-05-09 |
AU3319999A (en) | 1999-12-16 |
CN1238181A (zh) | 1999-12-15 |
NZ336001A (en) | 2000-09-29 |
PL333524A1 (en) | 1999-12-06 |
SG77244A1 (en) | 2000-12-19 |
ZA993345B (en) | 2000-08-22 |
ID23458A (id) | 2000-04-27 |
AR018862A1 (es) | 2001-12-12 |
HU9901830D0 (en) | 1999-07-28 |
KR20000005930A (ko) | 2000-01-25 |
EP0966966A3 (en) | 2000-02-09 |
NO992692L (no) | 1999-12-06 |
NO992692D0 (no) | 1999-06-03 |
IL130022A0 (en) | 2000-02-29 |
US6143325A (en) | 2000-11-07 |
HUP9901830A2 (hu) | 2001-06-28 |
PE20000544A1 (es) | 2000-06-29 |
JP2000007567A (ja) | 2000-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY25544A1 (es) | Forma de dosificación de nefazodona | |
ES2167061T3 (es) | Formas de dosificacion para mejorar la disfuncion erectil en pacientes de sexo masculino. | |
AR027091A1 (es) | Forma de dosificacion de farmacos accionada por un hidrogel | |
AR040722A1 (es) | Formulaciones y formas de dosificacion para la administracion controlada de topiramato | |
CR6326A (es) | Formulaciones farmaceuticas de liberacion controlada | |
DK1169024T3 (da) | Prægelatineret stivelse i en formulering med kontrolleret frigivelse | |
BR0112311A (pt) | Compostos e composições para liberar agentes ativos, forma de dosagem unitária, método para preparar ditas composições e seu uso | |
IT1271495B (it) | Composizione farmaceutica contenente 3-2 (dimetilammino) etil-n-metil-1h-indol-5-metansolfonammide, relativo procedimento di preparazione e impiego della stessa nel trattamento di mammiferi | |
BRPI0015567B8 (pt) | composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica | |
CO5190672A1 (es) | Composicion para la dosificacion oral, de disolucion instantanea | |
ECSP083351A (es) | Composiciones farmacéuticas | |
ATE302616T1 (de) | Oral anzuwendende arzneizusammensetzungen mit gesteuerter wirkstoffabgabe | |
AR039744A1 (es) | Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada | |
CO5170471A1 (es) | Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio | |
PT1383752E (pt) | 3-piperidinopropiofenonas deuteradas assim como farmacos contendo estes compostos | |
ATE541562T1 (de) | Ibuprofen-suspension | |
BR0210489A (pt) | Formulação farmacêutica oral, processo para preparar a mesma, uso da mesa, e método para preparar um distúrbio cardiovascular em um paciente | |
DE50005529D1 (de) | Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac | |
DE60102590T2 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
CO5200840A1 (es) | Combinacion de sustancias activas con clonidina | |
DK1345595T3 (da) | Ionstyrke-uafhængig farmaceutisk formulering med depotfrigivelse | |
ES2130081B1 (es) | Comprimido de maleato de trimebutina con recubrimiento laminar. | |
CO5580741A2 (es) | Composicion farmaceutica que comprende un agonista de receptor de 5ht1 | |
PE20030830A1 (es) | Ambroxol para el tratamiento de estados dolorosos en la cavidad bucal y faringea | |
AR034142A1 (es) | Una composicion farmaceutica, metodo para fabricar un medicamento en base a dicha composicion y uso de la composicion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
104 | Application deemed to be withdrawn (no substantive examination fee paid) |
Effective date: 20110826 |